- Home
- LSBK vs QNCX Comparison
LSBK vs QNCX Comparison
Compare LSBK & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- QNCX
- Stock Information
- Founded
- LSBK 1891
- QNCX 2012
- Country
- LSBK United States
- QNCX United States
- Employees
- LSBK N/A
- QNCX N/A
- Industry
- LSBK Savings Institutions
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSBK Finance
- QNCX Health Care
- Exchange
- LSBK Nasdaq
- QNCX Nasdaq
- Market Cap
- LSBK 90.0M
- QNCX 47.7M
- IPO Year
- LSBK 2006
- QNCX 2019
- Fundamental
- Price
- LSBK $15.85
- QNCX $2.00
- Analyst Decision
- LSBK
- QNCX Strong Buy
- Analyst Count
- LSBK 0
- QNCX 5
- Target Price
- LSBK N/A
- QNCX $8.00
- AVG Volume (30 Days)
- LSBK 6.1K
- QNCX 376.8K
- Earning Date
- LSBK 07-23-2025
- QNCX 08-12-2025
- Dividend Yield
- LSBK 3.40%
- QNCX N/A
- EPS Growth
- LSBK 27.62
- QNCX N/A
- EPS
- LSBK 0.89
- QNCX N/A
- Revenue
- LSBK $25,795,000.00
- QNCX N/A
- Revenue This Year
- LSBK N/A
- QNCX N/A
- Revenue Next Year
- LSBK N/A
- QNCX N/A
- P/E Ratio
- LSBK $17.81
- QNCX N/A
- Revenue Growth
- LSBK N/A
- QNCX N/A
- 52 Week Low
- LSBK $11.85
- QNCX $0.51
- 52 Week High
- LSBK $16.95
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- LSBK 50.07
- QNCX 70.90
- Support Level
- LSBK $15.22
- QNCX $1.55
- Resistance Level
- LSBK $16.20
- QNCX $1.71
- Average True Range (ATR)
- LSBK 0.15
- QNCX 0.15
- MACD
- LSBK -0.02
- QNCX 0.02
- Stochastic Oscillator
- LSBK 55.11
- QNCX 89.09
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.